Table 1.

Preclinical pharmacodynamics and pharmacokinetics of KRAS G12C inhibitors

	Sotorasib	Adagrasib	Divarasib
Max plasma concentration	7500 ng/mL	985 ng/mL	657 ng/mL
Recommended dose	960 mg daily	600 mg BID	400 mg daily
Half-life	5.5 h	23.0 h	17.6 h
AUC	65.3 h × mg/mL	37,139 h × ng/mL	9130 h × ng/mL